MedTrace Logo

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

NCT06484920 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-10

No results posted yet for this study

Summary

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

Conditions

  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • B-cell Lymphoma

Interventions

DRUG

ATRA

150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)

DRUG

Pembrolizumab

200mg Q3W pembrolizumab

Sponsors & Collaborators

  • Rita Assi

    lead OTHER

Principal Investigators

  • Rita Assi, MD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2027-12-31
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06484920 on ClinicalTrials.gov